Abstract
Introduction: Frequent home-based spirometry may provide more accurate estimates of lung function in patients with IPF than intermittent spirometry performed at clinic visits.
Aim: To assess the relationship between home and clinic spirometry in the INMARK trial.
Methods: Subjects with IPF and FVC ≥80% predicted were randomised to receive nintedanib or placebo for 12 weeks, followed by open-label nintedanib for 40 weeks. Subjects were asked to perform home spirometry at least once a week and ideally daily. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Correlations between home and clinic measurements of FVC (mL) and FEV6 (mL) at each time point, and between home- and clinic-measured rates of FVC decline at each time point, were assessed using Pearson correlation coefficients (r).
Results: Among all treated subjects (n=346), strong correlations were observed between home and clinic measurements of FVC (r=0.72 to 0.84) and FEV6 (r=0.71 to 0.85) at all time points. In the 116 subjects treated with nintedanib for 52 weeks, home- and clinic-measured rates of FVC decline were −127 and −89 mL/52 weeks, respectively, and the home-measured rate of FEV6 decline was −113 mL/52 weeks. Correlations between rates of FVC decline based on home versus clinic spirometry were weak but increased over 52 weeks (r=0.00 and r=0.26 for the rate of decline over 4 and 52 weeks, respectively).
Conclusions: In subjects with IPF and preserved FVC, home and clinic measurements of FVC and FEV6 at visits over 52 weeks were strongly correlated. These data suggest that home-based spirometry might be a feasible way to monitor lung function in patients with IPF over 52 weeks.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA1318.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019